Latest news

Debiopharm reinforces the bond between Swiss and Japanese cancer research with the 2022 JCA-Mauvernay Award Ceremony

Big Impact, Small Package: Debiopharm Launches a Wazoku Open-Innovation Challenge for Small Antibody Drug Conjugate Technology

Debiopharm Co-leads a 10M USD Series A Round to Accelerate the Development of Genomic Medicines through Artificial Intelligence

One drug for one bug: Debiopharm to discuss the potential of pathogen-specific antibiotics at the 2022 World AMR Congress

Debiopharm’s new agreement with the University of Geneva boosts scientific Innovation Hub in the Lemanic region of Switzerland through the…

Paul Scherrer Institute regains License from Debiopharm for the Development of Tageted Radiopharmaceutical Debio 1124

7e Challenge Qualité de vie du patient : cinq finalistes reçoivent 5000 francs chacun et avancent en finale

Debiopharm leads investment round for evidence-based digital cancer therapeutic app Mika to empower cancer patients

VivoSense Announces Closing of $25M Series A Financing Round Co-led by Xontogeny and Debiopharm